Literature DB >> 26780351

Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.

Frederic I Preffer, Constance M Yuan, Pei Lin, MaryAlice Stetler-Stevenson, Gerald E Marti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26780351      PMCID： PMC7821959          DOI： 10.1002/cyto.b.21342

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN： 1552-4949            Impact factor:   3.058


× No keyword cloud information.
  11 in total

1.  Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Authors:  Maryalice Stetler-Stevenson; Bruno Paiva; Lloyd Stoolman; Pei Lin; Jeffrey L Jorgensen; Alberto Orfao; Jacques Van Dongen; Andy C Rawstron
Journal:  Cytometry B Clin Cytom       Date:  2015-07-06       Impact factor: 3.058

Review 2.  Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.

Authors:  Brent L Wood
Journal:  Cytometry B Clin Cytom       Date:  2015-05-29       Impact factor: 3.058

3.  Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.

Authors:  Fanny Pojero; Juan Flores-Montero; Luzalba Sanoja; José Juan Pérez; Noemí Puig; Bruno Paiva; Sebastian Bottcher; Jacques J M van Dongen; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2015-07-31       Impact factor: 3.058

Review 4.  Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Authors:  Andy C Rawstron; Ruth M de Tute; J Haughton; Roger G Owen
Journal:  Cytometry B Clin Cytom       Date:  2015-12-21       Impact factor: 3.058

Review 5.  Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.

Authors:  Juan Flores-Montero; Ruth de Tute; Bruno Paiva; José Juan Perez; Sebastian Böttcher; Henk Wind; Luzalba Sanoja; Noemí Puig; Quentin Lecrevisse; María Belén Vidriales; Jacques J M van Dongen; Alberto Orfao
Journal:  Cytometry B Clin Cytom       Date:  2015-07-31       Impact factor: 3.058

6.  Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Authors:  Nicole J Gormley; Danielle M Turley; Jennifer S Dickey; Ann T Farrell; Gregory H Reaman; Elizabeth Stafford; Lea Carrington; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2015-07-25       Impact factor: 3.058

7.  Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Authors:  Teri A Oldaker; Paul K Wallace; David Barnett
Journal:  Cytometry B Clin Cytom       Date:  2015-09-04       Impact factor: 3.058

8.  Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Authors:  Andy C Rawstron; Bruno Paiva; Maryalice Stetler-Stevenson
Journal:  Cytometry B Clin Cytom       Date:  2015-09-23       Impact factor: 3.058

9.  Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Authors:  Maria Arroz; Neil Came; Pei Lin; Weina Chen; Constance Yuan; Anand Lagoo; Mariela Monreal; Ruth de Tute; Jo-Anne Vergilio; Andy C Rawstron; Bruno Paiva
Journal:  Cytometry B Clin Cytom       Date:  2015-06-02       Impact factor: 3.058

10.  Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.

Authors:  Vittorio Emanuele Muccio; Elona Saraci; Milena Gilestro; Valter Gattei; Antonella Zucchetto; Monica Astolfi; Marina Ruggeri; Eleonora Marzanati; Roberto Passera; Antonio Palumbo; Mario Boccadoro; Paola Omedè
Journal:  Cytometry B Clin Cytom       Date:  2015-09-23       Impact factor: 3.058
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.